- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05671692
Novel Intervention for Chronic Complex TBI in OEF/OIF/OND Veterans
The goal of this clinical trial is to compare pregnenolone and placebo (a placebo is a look-alike substance that contains no active drug) in Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND)-Era Veterans with a history of chronic Traumatic Brain Injury (TBI). The main questions it aims to answer are:
- Does pregnenolone improve psychological health, overall physical function, cognition, symptoms of PTSD, and pain more than placebo over the 8-week study period, and what is the most effective dose of the drug that is safe and well-tolerated?
- What are the biological effects of pregnenolone, and how do pregnenolone and other molecules change over the course of treatment? (and do pregnenolone and other molecules predict clinical improvement?)
Participants who are eligible and consent to participate in the study will:
- be randomized in a 1:1 ratio to take pregnenolone or placebo
- be given pregnenolone or placebo to take each day at home
- will participate in 6 visits over 11 weeks for tests, exams and procedures that are for study purposes (each visit will last 1.5 - 3 hours)
- be evaluated at each visit to determine if there are any bad reactions to the study drug and if study participation is still appropriate
- be financially compensated for their visit time and travel cost
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Susan O'Loughlin
- Phone Number: 919-384-8582
- Email: susan.oloughlin@duke.edu
Study Contact Backup
- Name: Jason Kilts, PhD
- Phone Number: 919-286-0411
- Email: jason.kilts@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 21-65 years of age, any ethnic group, either sex.
- History of mild TBI since 2001 and service in the U.S. Military since 9/11/01 (OEF/OIF/OND era).
- We will adhere to the operational definition of mild TBI suggested by the World Health Organization Task Force (Holm et al 2005), with the exception of Glasgow Coma Scale score criteria (not available for these participants): a.) 1 or more of the following: confusion or disorientation, loss of consciousness for 30 minutes or less, post-traumatic amnesia for less than 24 hours, and/or other transient neurological abnormalities such as focal signs, seizure, and intracranial lesion not requiring surgery; Glasgow Coma Scale (GCS) score of 13-15 after 30 minutes post-injury or later upon presentation for health care (GCS unavailable). This WHO diagnostic definition of mild TBI is also consistent with the CDC Report to Congress on Mild TBI in the United States, September 2003 (specifically, altered consciousness attributable to the head injury [=transient confusion, disorientation or impaired consciousness] or self-reported loss of consciousness lasting 30 minutes or less).
- Ability to read/understand English and to participate fully in the informed consent process.
- No anticipated need to alter psychiatric or pain medications for duration of study involvement.
- No changes in psychotropic or behavioral interventions during the study or in the 2 weeks prior to study enrollment.
- Negative pregnancy test if female. Sexually active subjects are required to use a medically acceptable form of birth control if they are of childbearing potential and could become pregnant during the study.
Exclusion Criteria:
- Exclusionary criteria will diverge slightly from the above WHO definition of mild TBI and exclude participants who report a history of seizures for this investigation.
- Participants with current suicidal or homicidal ideation necessitating clinical intervention or representing an imminent concern.
- Concomitant medications for co-occurring medical conditions are permissible for stable medical conditions that are reasonably well-controlled (for example, hypertension medications, statins, and oral hypoglycemic medications would generally be permissible if they appear to be effectively treating the underlying condition). Medications that could potentially confound study outcomes (for example, prednisone) are exclusionary.
- Participants who report a history of seizures, a history of stroke, a history of prostate cancer (or any other cancer other than non-melanoma skin cancer), a history of myocardial infarction, the presence of congestive heart failure, or any other serious health condition that would likely preclude safe study participation in the medical opinion of the PI or in consultation with the participant's PCP/other health care provider).
- Current DSM-5 diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than TBI.
- Female participants who are pregnant or breast-feeding.
- Known allergy to study medication.
- Benzodiazepine or opioid use within the last 2 weeks is exclusionary.
- Substance use disorder (DSM-5), other than nicotine use disorder.
- Serious unstable medical illness. History of cerebrovascular accident, prostate, uterine or breast cancer. Medications to treat these conditions either acutely or chronically (for example, finasteride, tamoxifen, clopidogrel) are also exclusionary.
- Use of oral contraceptives or other hormonal supplementation such as estrogen or progesterone, as there is a theoretical risk that a metabolite of pregnenolone could potentially impact efficacy of oral contraceptives and estrogen replacement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Same as active comparator, except placebo dispensed.
|
Active Comparator: Pregnenolone
|
Pregnenolone 250 mg BID x 14 DAYS, followed by Pregnenolone 500 mg BID x 14 DAYS, followed by Pregnenolone 1000 mg BID x thereafter for the remainder of the 8-week trial
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in psychological health as measured by the Brief Symptom Inventory-18 (BSI)
Time Frame: Baseline, week 8
|
The BSI-18 GSI summarizes a respondent's overall level of psychological distress.
The score used in a normatively based T-score (range 1-100) calculated from the sum of responses.
Higher scores are indicative of greater distress.
The outcome measure is the change in scores before and after treatment (the baseline and Week 8 difference scores).
|
Baseline, week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in physical health as measured by the 36-Item Short Form Health Survey (SF-36)
Time Frame: Baseline, week 8
|
These data report changes in the mean scores in physical health symptoms using the Physical Health Summary sub score of the SF-36.
The SF-36 is a health survey with an 8-scale profile embedded in 36 questions that measures components of health.
Each item is scored on a 0 to 100 range, with the lowest and highest possible scores set at 0 and 100, respectively.
All of these items are scored such that a high score defines a more favorable health state.
Thus, increases in scores represent improvements relative to baseline.
|
Baseline, week 8
|
Changes in mental health as measured by the 36-Item Short Form Health Survey (SF-36)
Time Frame: Baseline, week 8
|
These data report changes in the mean scores in mental health symptoms using the Mental Health Summary sub score of the SF-36.
The SF-36 is a health survey with an 8-scale profile embedded in 36 questions that measures components of health.
Each item is scored on a 0 to 100 range, with the lowest and highest possible scores set at 0 and 100, respectively.
All of these items are scored such that a high score defines a more favorable health state.
Thus, increases in scores represent improvements relative to baseline.
|
Baseline, week 8
|
Changes in cognition as measured by the Wechsler Adult Intelligence Scale (WAIS-IV)
Time Frame: Baseline, week 8
|
WAIS-IV coding test is a valid and sensitive measure of cognitive dysfunction that correlates with functional outcomes.
The participant is required to identify the symbols matched to numbers using a key and write in the symbol beneath the associated number.
The total score ranges from 0 to 135 and is based on the total number of codes correctly completed over a 90-second time limit.
Higher scores indicate better processing speed.
Positive change from baseline indicates better processing speed.
|
Baseline, week 8
|
Changes in cognition as measured by the Stroop Color and Word Test (STROOP)
Time Frame: Baseline, week 8
|
The Stroop is a neuropsychological test extensively used to assess the ability to inhibit cognitive interference that occurs when the processing of a specific stimulus feature impedes the simultaneous processing of a second stimulus attribute, well-known as the Stroop Effect.
The score for the Stroop Test is the number of correct responses provided in 45 seconds on each test condition: word reading, color naming, and inhibition.
Scores range from 0 to no upper limit, with higher scores indicating better performance.
|
Baseline, week 8
|
Changes in PTSD symptoms as measured by the PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Baseline, week 8
|
Post-Traumatic Stress Disorder (PTSD) symptoms will be evaluated by the Post-Traumatic Stress Disorder Checklist Scale-Version DSM 5 (PCL-5).
This questionnaire contains twenty items to assess PTSD symptoms.
A total score for symptom severity (0-80) can be obtained by summing the scores for each of the 20 items.
Higher scores are indicative of greater symptomatology.
|
Baseline, week 8
|
Changes in depression symptoms as measured by the Beck Depression Inventory-II (BDI-II)
Time Frame: Baseline, week 8
|
The BDI-II is a 21-item, self-report rating inventory that assesses symptoms of depression.
Scores range from 0 (no depression) to 63 (severe depression).
Higher scores indicate greater depression symptomatology.
|
Baseline, week 8
|
Changes in pain symptoms as measured by the Brief Pain Inventory (BPI)
Time Frame: Baseline, week 8
|
The Brief Pain Inventory (BPI) is a self-reported scale that measures the severity of pain symptoms.
The scores range from 0 (no pain) to 10 (pain as severe as you can imagine).
The Interference scores range from 0 (does not interfere) to 10 (completely interferes); there are 7 questions assessing the interference of pain.
The outcome measure is the change in scores before and after treatment (the baseline and Week 8 difference scores).
Higher scores are associated with greater pain.
|
Baseline, week 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chris Marx, MD, Duke University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00111732
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Traumatic Brain Injury
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
-
Institut National de la Santé Et de la Recherche...Institut National de Recherche en Informatique et en AutomatiqueNot yet recruitingTBI (Traumatic Brain Injury)France
-
University of Sao Paulo General HospitalUnknownTraumatic Brain Injury | Severe Brain Injury | Closed Traumatic Brain InjuryBrazil
-
Queen Mary University of LondonCompleted
-
Northeastern UniversityBrandeis UniversityRecruitingTraumatic Brain Injury | Mild Traumatic Brain Injury | TBI | Moderate Traumatic Brain InjuryUnited States
Clinical Trials on Pregnenolone
-
Weill Medical College of Cornell UniversityStanley Medical Research InstituteCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
University of ChicagoUnknown
-
University of Texas Southwestern Medical CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedMajor Depressive DisorderUnited States
-
VA Office of Research and DevelopmentNot yet recruitingAnxiety and DepressionUnited States
-
National Research Foundation, SingaporeDuke University; National University, Singapore; Singapore Clinical Research...Completed
-
University of Texas Southwestern Medical CenterStanley Medical Research InstituteCompletedBipolar Disorder | Major Depressive Disorder | Substance AbuseUnited States
-
Stanford UniversityCompleted
-
Medical University of South CarolinaCompleted
-
Stanford UniversitySimons FoundationRecruiting
-
Durham VA Medical CenterCompleted